Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 9/20 | 0.72 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.61 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30821677 | 1.00 | BCHE (0.72) | BCHECYP4F2CYP4A11MAPK1LMNA | |
| SCHEMBL10011367 | 0.97 | BCHE (0.76) | BCHECYP4F2CYP4A11MAPK1MEN1 | |
| SCHEMBL30821452 | 0.97 | BCHE (0.76) | BCHECYP4F2CYP4A11MAPK1MEN1 | |
| SCHEMBL21634358 | 0.89 | SMN1; SMN2 (0.64) | BCHELMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL21634276 | 0.89 | MEN1 (0.62) | BCHEMAPK1LMNAMEN1KMT2A | |
| SCHEMBL30821480 | 0.89 | SMN1; SMN2 (0.64) | BCHELMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL23120424 | 0.89 | BCHE (0.77) | BCHECYP4F2CYP4A11MAPK1MEN1 | |
| SCHEMBL14704473 | 0.87 | BCHE (0.60) | BCHECYP4F2CYP4A11LMNARAB9A | |
| SCHEMBL21634318 | 0.86 | SMN1; SMN2 (0.67) | BCHELMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL21634323 | 0.86 | MEN1 (0.65) | BCHEMAPK1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163399-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING PROTEINOPATHIES COMPRING THE SAME | PROTECH CO., LTD. (KR) | 2021-06-03 | — | — | US | claimed |
| EP-3828163-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME | Protech Co., Ltd. (KR) | 2021-06-02 | — | — | EP | claimed |
| WO-2020022784-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME | 주식회사 프로텍바이오 | 2020-01-30 | — | — | WO | claimed |
| US-12427346-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | AUTOTAC INC. (KR) | 2025-09-30 | — | — | US | disclosed |
| CN-112424160-B | Novel P62 ligand compound and composition for preventing, improving or treating protein conformational diseases comprising the same | 奧土择破利悟株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20210163399-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING PROTEINOPATHIES COMPRING THE SAME | PROTECH CO., LTD. (KR) | 2021-06-03 | — | — | US | disclosed |
| EP-3828163-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME | Protech Co., Ltd. (KR) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020022784-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME | 주식회사 프로텍바이오 | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163399-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING PROTEINOPATHIES COMPRING THE SAME | SQSTM1, ATG7, BECN1 | BCHE 3322/4885CYP4F2 4355/4885CYP4A11 3690/4885 |
| US-12427346-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | SQSTM1, ATG7, BECN1 | BCHE 3594/4885CYP4F2 4416/4885CYP4A11 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.